arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Larimar Therapeutics, Inc.

LRMR
$3.87 ▲ +0.05 (+1.18%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Larimar Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC -21.3%
FCF / Share None
Trailing P/E
Price / Book 3.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-29.61M
↓ -1.1%
FCF / Share Free cash flow per share
$-0.42
↓ -113.8%
Long-Term Debt Long-term obligations
$16.36M
↓ -10.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 56 quarters